Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Psychogeriatrics. 2009 Dec;9(4):157-66. doi: 10.1111/j.1479-8301.2010.00307.x.
In tauopathies, tau protein is hyperphosphorylated, ubiquitinated, and accumulated in the brain; however, the mechanisms underlying this accumulation remain unclear. To gain an understanding of the role of proteases in the metabolism of tau protein, in the present study we evaluated the effects of protease inhibitors in SH-SY5Y human neuroblastoma cells and COS-7 cells transfected with the tau gene. When cells were treated with 0.1-10 micromol/L of lactacystin and 1.0-20 micromol/L of MG-132 (inhibitors of proteasome), 0.1-10 micromol/L of CA-074Me (a cathepsin inhibitor), and 0.1-2 micromol/L of puromycin (a puromycin-sensitive aminopeptidase (PSA) inhibitor) for up to 24 h, there were no significant changes in tau protein levels. However, pulse-chase experiments demonstrated that the proteolysis of tau protein in SH-SY5Y cells was attenuated following treatment of cells with 200 nmol/L puromycin. Increased tau protein levels were also observed in SH-SY5Y cells treated with short interference (si) RNA to PSA to inhibit the expression of PSA. These data suggest that PSA is a protease that catalyses tau protein predominantly in SH-SY5Y cells. The protein metabolism of tau-containing mutations of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) was also investigated using pulse-chase experiments. The results indicate attenuated proteolysis of tau in cells transfected with mutant tau genes after 48 h. Further immunocytochemical analysis and subcellular fractionation experiments revealed that the mutations did not alter the intracellular distribution of tau and suggested that impaired accessibility of tau to PSA is unlikely to account for the attenuated proteolysis of tau protein. Western blotting with phosphorylation-dependent antibodies revealed that phosphorylation levels of tau at Thr(231), Ser(396), and Ser(409) were increased in cells transfected with V337M, R406W, and R406W mutant tau genes, respectively. Together, the data suggest that attenuated proteolysis of FTDP-17 mutant tau may be explained by increased phosphorylation levels, resulting in resistance to proteolysis.
在神经原纤维缠结病中,tau 蛋白过度磷酸化、泛素化并在大脑中积累;然而,这种积累的机制尚不清楚。为了了解蛋白酶在 tau 蛋白代谢中的作用,本研究评估了蛋白酶抑制剂在转染 tau 基因的 SH-SY5Y 人神经母细胞瘤细胞和 COS-7 细胞中的作用。当细胞用 0.1-10 μmol/L 的 lactacystin 和 1.0-20 μmol/L 的 MG-132(蛋白酶体抑制剂)、0.1-10 μmol/L 的 CA-074Me(组织蛋白酶抑制剂)和 0.1-2 μmol/L 的 puromycin(对氨酰脯氨酸内肽酶 PSA 的抑制剂)处理长达 24 小时时,tau 蛋白水平没有明显变化。然而,脉冲追踪实验表明,在用 200 nmol/L puromycin 处理细胞后,SH-SY5Y 细胞中的 tau 蛋白水解被减弱。在用 PSA 的短干扰 RNA(siRNA)处理 SH-SY5Y 细胞以抑制 PSA 的表达后,tau 蛋白水平也升高。这些数据表明 PSA 是一种主要在 SH-SY5Y 细胞中催化 tau 蛋白的蛋白酶。使用脉冲追踪实验还研究了含有额颞叶痴呆和帕金森病相关染色体 17(FTDP-17)突变的 tau 蛋白的蛋白质代谢。结果表明,转染突变 tau 基因的细胞在 48 小时后 tau 蛋白的水解被减弱。进一步的免疫细胞化学分析和亚细胞分离实验表明,这些突变并未改变 tau 的细胞内分布,并提示 tau 对 PSA 的易接近性受损不太可能导致 tau 蛋白水解减弱。用磷酸化依赖性抗体进行的 Western 印迹显示,在用 V337M、R406W 和 R406W 突变 tau 基因转染的细胞中,tau 蛋白在 Thr(231)、Ser(396)和 Ser(409)处的磷酸化水平分别增加。综上所述,数据表明 FTDP-17 突变 tau 的水解减弱可能是由于磷酸化水平增加导致对水解的抗性增强所致。